These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30924071)

  • 21. The impact of different scenarios for intermittent bladder catheterization on health state utilities: results from an internet-based time trade-off survey.
    Averbeck MA; Krassioukov A; Thiruchelvam N; Madersbacher H; Bøgelund M; Igawa Y
    J Med Econ; 2018 Oct; 21(10):945-952. PubMed ID: 29882712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD).
    Matza LS; Stewart KD; Fournier M; Rowen D; Lachmann R; Scarpa M; Mengel E; Obermeyer T; Ayik E; Laredo F; Pulikottil-Jacob R
    Eur J Health Econ; 2024 Nov; 25(8):1437-1448. PubMed ID: 38409492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
    Hall F; de Freitas HM; Kerr C; Ito T; Nafees B; Lloyd AJ; Penton J; Hadi M; Lanar S; Pham TP
    Qual Life Res; 2019 May; 28(5):1191-1199. PubMed ID: 30767088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
    Schwedt TJ; Martin A; Kymes S; Talon B; Lee XY; Cady R; Asher D; Karnik-Henry M; Mulvihill E; Bates D; Beusterien K
    Headache; 2023 Apr; 63(4):484-493. PubMed ID: 36753057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health state utilities associated with post-surgical Staphylococcus aureus infections.
    Matza LS; Kim KJ; Yu H; Belden KA; Chen AF; Kurd M; Lee BY; Webb J
    Eur J Health Econ; 2019 Aug; 20(6):819-827. PubMed ID: 30887157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).
    Matza LS; Brazier JE; Stewart KD; Pinto L; Bender RH; Kircik L; Jordan J; Kim KJ; Mutebi A; Viswanathan HN; Menter A
    J Med Econ; 2019 Sep; 22(9):936-944. PubMed ID: 31161828
    [No Abstract]   [Full Text] [Related]  

  • 27. Health state utilities for migraine based on attack frequency: a time trade-off study.
    Rencz F; Brodszky V; Péntek M; Bereczki D; Gulácsi L
    Neurol Sci; 2015 Feb; 36(2):197-202. PubMed ID: 25108469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients' preference for migraine preventive therapy.
    Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
    Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.
    Boye KS; Matza LS; Walter KN; Van Brunt K; Palsgrove AC; Tynan A
    Eur J Health Econ; 2011 Jun; 12(3):219-30. PubMed ID: 20224930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient and public preferences for health states associated with AMD.
    Butt T; Dunbar HM; Morris S; Orr S; Rubin GS
    Optom Vis Sci; 2013 Aug; 90(8):855-60. PubMed ID: 23811607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.
    Castejón N; Cappelleri JC; Cuervo J; Lang K; Mehta P; Mokgokong R; Mamolo C
    Health Qual Life Outcomes; 2018 Apr; 16(1):66. PubMed ID: 29669568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension.
    Davies EW; Llewellyn S; Beaudet A; Kosmas CE; Gin-Sing W; Doll HA
    Patient Prefer Adherence; 2018; 12():1079-1088. PubMed ID: 29950821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating health state utilities in primary hyperoxaluria type 1: a valuation study.
    de Freitas HM; Danese D; Hubig L; Lloyd A; Lombardelli S
    J Med Econ; 2023; 26(1):386-393. PubMed ID: 36852648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study.
    Beusterien KM; Davies J; Leach M; Meiklejohn D; Grinspan JL; O'Toole A; Bramham-Jones S
    Health Qual Life Outcomes; 2010 May; 8():50. PubMed ID: 20482804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study.
    Seo J; Smith CA; Thomas C; Tervonen T; Hareendran A; Ford JH; Stauffer VL; Nicholson RA; Duffy KH; Tockhorn-Heidenreich A
    Patient; 2022 Jan; 15(1):93-108. PubMed ID: 34131880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.
    Holko P; Kawalec P; Mossakowska M
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):174-180. PubMed ID: 29194233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.
    Sundaram M; Smith MJ; Revicki DA; Miller LA; Madhavan S; Hobbs G
    Pharmacoeconomics; 2010; 28(3):201-16. PubMed ID: 20151725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EuroQol (EQ-5D) health utility scores for patients with migraine.
    Xu R; Insinga RP; Golden W; Hu XH
    Qual Life Res; 2011 May; 20(4):601-8. PubMed ID: 21063786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment.
    Bougie JK; Krupsky K; Beusterien K; Ladouceur MP; Mulvihill E
    Headache; 2024 Jul; ():. PubMed ID: 38982656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.
    Matza LS; Cong Z; Chung K; Stopeck A; Tonkin K; Brown J; Braun A; Van Brunt K; McDaniel K
    Patient Prefer Adherence; 2013; 7():855-65. PubMed ID: 24039408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.